
|Slideshows|March 2, 2017
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Author(s)Samantha J. Peterson
Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Advertisement
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
2
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Building the Foundation for Earlier Alzheimer Disease Diagnosis
5

















